Fusion Antibodies (LON:FAB) Releases Earnings Results

Fusion Antibodies (LON:FAB) issued its quarterly earnings results on Monday. The company reported GBX (1.20) earnings per share for the quarter, Digital Look Earnings reports. Fusion Antibodies had a negative return on equity of 210.32% and a negative net margin of 91.92%.

Fusion Antibodies Trading Down 15.2%

LON FAB opened at GBX 9.62 on Monday. The stock has a market cap of £12.05 million, a PE ratio of -6.42 and a beta of 1.24. The company has a current ratio of 1.80, a quick ratio of 2.36 and a debt-to-equity ratio of 92.42. Fusion Antibodies has a 12 month low of GBX 9.10 and a 12 month high of GBX 21. The company’s 50-day moving average price is GBX 10.89 and its 200-day moving average price is GBX 12.20.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.